Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

AEZS Articles Aeterna Zentaris Inc.

home / stock / aezs / aezs articles

AEZS AEZS Quote AEZS Short AEZS News AEZS Articles AEZS Message Board

Articles | Aeterna Zentaris Inc. (NASDAQ:AEZS)

  • Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | Benzinga

    TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro ...

    • March 28, 2024 11:55:00 am
    • |
    • Benzinga
    • |
      • AEZS Stock
      • AEZS Quote
      • AEZS Short
      • AEZS News
      • AEZS Articles
      • AEZS Message Board
Stock Information
Get AEZS Alerts

News, Short Squeeze, Breakout and More Instantly...

Aeterna Zentaris Inc. Company Name:

AEZS Stock Symbol:

NASDAQ Market:

3.76% G/L:

$5.72 Last:

7,563 Volume:

$5.505 Open:

$5.72 Close:

Aeterna Zentaris Inc. Website:

Aeterna Zentaris Inc. Logo

Ad

Investor Relations
RECENT AEZS NEWS
  • AEZS - COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

    TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pha...

  • AEZS - COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

    - Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of macimorelin confirmed in the pediatric population TORONTO, ONTARIO, Aug. 27,...

  • AEZS - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

    Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8 million in cash TORONTO, ONTARIO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CS...

  •
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.

Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get AEZS Alerts

Get AEZS Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.

Forgot password?


Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord

Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1